Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021

HomeACQUISITIONS and MERGERSEarlySense Sells IP To Hillrom for $30M+ - Focuses on Virtual/Home Patient...

EarlySense Sells IP To Hillrom for $30M+ – Focuses on Virtual/Home Patient Monitoring

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

February 1, 2021

EarlySense, the global leader in contact-free, continuous monitoring solutions across the healthcare continuum, announced today that it has sold proprietary contact-free continuous monitoring technology to Hillrom (NYSE: HRC).

Early Sense notes under terms of the agreement, EarlySense will receive licensing for all intellectual property and technology sold to Hillrom for use outside the hospital, as well as a cash consideration of $30 million, potential payments based on the achievement of certain commercial milestones, and a portion of Hillrom’s equity investment in EarlySense.

“We set out to save lives and improve care by implementing AI-based contact-free patient monitoring in healthcare facilities across the globe,” said Matt Johnson, CEO of EarlySense. “We made great progress by becoming the standard of care in Hillrom’s flagship Centrella® Smart+ hospital bed. Our technology has already monitored more than one million patients and helped clinicians save tens of thousands of lives, and we expect to accelerate this significant impact as a result of this technology sale to Hillrom.

“The COVID-19 pandemic has created historic opportunities for smart health technologies outside the hospital, and this transaction will allow us to continue serving our global customer base and apply our clinically proven technology to this high-growth sector. Our more than one hundred million patient-monitored hours uniquely position us to deliver intelligent, predictive, and patented solutions that elevate remote patient care without increasing the risk of harmful infection,” added Johnson.

EarlySense technology allows for the continuous (more than 100 times per minute) monitoring of patient heart and respiratory rates without ever touching the patient. The technology also alerts clinicians to potential patient deterioration events much earlier than traditional monitoring methods. This technology serves as the engine for EarlySense remote patient monitoring devices, helping bring hospital-grade patient analytics to care settings outside the hospital.

“EarlySense’s contact-free continuous monitoring technology provides caregivers with a full picture of patient health, allowing for intervention at the earliest signs of patient deterioration,” said Hillrom President and CEO John Groetelaars. “We look forward to bringing this critical technology to additional customers around the world as we deliver on our vision of Advancing Connected Care™.”

Wells Fargo Securities served as exclusive financial advisor to EarlySense and Goldfarb & Seligman and Polsinelli served as legal counsel.

spot_img

DON'T MISS

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy